Keytruda beaten by Summit’s bispecific in NSCLC

On 8 September 2024, Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific monoclonal antibody that binds to vascular endothelial growth factor A and programmed cell death protein 1 (PD-1), head-to-head with Merck‘s Keytruda, a PD-1 binding checkpoint inhibitor, in non-small cell lung cancer (NSCLC) patients with a PD-L1 tumour proportion score (TPS) above 1%.